Capricor
Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner
United States Food and Drug Administration, Capricor, deramiocel, Market, Review [Publication Type], Biologics License Application, first
Capricor Secures $35M Deal for European Rights to DMD Therapy Ahead of FDA Application
Capricor Therapeutics, Duchenne muscular dystrophy (DMD), cell therapy, FDA application, European rights, $35M deal